Peptide Comparison

Compare peptides side-by-side.

Pick up to four peptides and compare mechanism, evidence grade, pharmacokinetics, administration and risk profile in a single view.

Selection · 3 / 4

Save & share

Save a set to reload it later on this device, or copy a share link to send the exact comparison to someone else.

Export comparison

Download the full side-by-side table as a landscape PDF for reading, or a CSV for spreadsheets and further analysis.

AI comparison summary

Biggest differences across BPC-157 · TB-500 · Retatrutide

Focused on evidence grade, pharmacokinetics, and risks/interactions — with inline citations to the primary references on each peptide page.

Click Generate summary to have AI highlight the biggest differences between the peptides you've selected.

BPC-157

Grade BRegenerative

Overview

Evidence grade: Grade B
Category: Regenerative
Primary focus: Tissue repair, gut integrity
Summary: Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.

Mechanism

Mechanism of action: Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous or oral (gut-localized)
Half-life: ~4 hours (subcutaneous)
PK notes: BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~4 hours (subcutaneous). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

Administration

Typical dose: 250–500 mcg
Frequency: 1–2× daily
Cycle length: 4–6 weeks on, 4 weeks off
Timing: Near site of injury or AM/PM fasted
Protocol steps: Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily.
Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible.
Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Accelerated soft-tissue recovery in preclinical models
Gut barrier integrity and ulcer protection
Potential nervous system neuroprotection
Common stacks: TB-500, Collagen peptides, Vitamin C

Risks

Side effects: Generally well tolerated in animal studies
Injection site irritation
Long-term human safety unknown
Contraindications: Active malignancy (theoretical angiogenic concern)
Pregnancy and lactation
Interactions: Anticoagulants — Theoretical synergy via NO modulation — monitor.
VEGF inhibitors — Mechanistic opposition; avoid combination.
Legal status: Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

TB-500

Grade BRegenerative

Overview

Evidence grade: Grade B
Category: Regenerative
Primary focus: Soft tissue regeneration
Summary: Widely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.

Mechanism

Mechanism of action: Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous or intramuscular injection
Half-life: ~2 hours (short systemic), with sustained tissue effects
PK notes: TB-500 is administered subcutaneous or intramuscular injection with an approximate systemic half-life of ~2 hours (short systemic), with sustained tissue effects. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2× per week loading (4 weeks), then 2–5 mg weekly maintenance) is designed to match receptor kinetics rather than plasma exposure. Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.

Administration

Typical dose: 2–5 mg
Frequency: 2× per week loading (4 weeks), then 2–5 mg weekly maintenance
Cycle length: 6–8 week loading phase, then maintenance
Timing: Any time of day; rotate injection sites
Protocol steps: Route: Subcutaneous or intramuscular injection. Typical starting dose 2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance.
Timing: Any time of day; rotate injection sites — keep it the same each dosing day to make effects legible.
Cycle length: 6–8 week loading phase, then maintenance. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Accelerated soft-tissue and tendon recovery in preclinical models
Improved range of motion after acute injury (case reports)
Wound healing and reduced fibrosis
Cardiac repair signal in animal MI models
Common stacks: BPC-157, Collagen peptides, Vitamin C

Risks

Side effects: Injection site reactions
Temporary lethargy or head rush after dosing
Long-term human safety not characterized
Contraindications: Active malignancy (theoretical angiogenic concern)
Pregnancy and lactation
Interactions: Anticoagulants — Theoretical effect on tissue remodeling — caution.
BPC-157 — Frequently co-stacked; no formal interaction studies.
Legal status: WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.

Retatrutide

Grade AMetabolic

Overview

Evidence grade: Grade A
Category: Metabolic
Primary focus: Triple GIP/GLP-1/glucagon agonist
Summary: Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.

Mechanism

Mechanism of action: First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Evidence explainer: Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.

Pharmacokinetics

Route: Subcutaneous injection
Half-life: ~6 days (supports once-weekly dosing)
PK notes: Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.

Administration

Typical dose: Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency: Once weekly
Cycle length: Ongoing; weight regain occurs on cessation
Timing: Same day each week; any time of day
Protocol steps: Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly.
Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible.
Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: ~24% mean weight loss at 48 weeks (Phase II)
Marked improvements in HbA1c, blood pressure, ApoB and liver fat
Convenient once-weekly dosing
Likely best-in-class cardiometabolic profile
Common stacks: Creatine monohydrate, Whey protein, Vitamin D3 + K2

Risks

Side effects: Nausea, vomiting, diarrhea (especially during titration)
Injection site reactions
Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting
Theoretical pancreatitis and gallbladder risk (class effect)
Contraindications: Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia type 2
Pregnancy and lactation
Prior severe reaction to GLP-1 agonists
Interactions: Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required.
Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Legal status: Investigational; not yet FDA-approved. Currently available only via clinical trials.

Attribute	BPC-157 Grade BRegenerative	TB-500 Grade BRegenerative	Retatrutide Grade AMetabolic
Overview
Evidence grade	Grade B	Grade B	Grade A
Category	Regenerative	Regenerative	Metabolic
Primary focus	Tissue repair, gut integrity	Soft tissue regeneration	Triple GIP/GLP-1/glucagon agonist
Summary	Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.	Widely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.	Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.
Mechanism
Mechanism of action	Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.	Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.	First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Evidence explainer	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.	Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.
Pharmacokinetics
Route	Subcutaneous or oral (gut-localized)	Subcutaneous or intramuscular injection	Subcutaneous injection
Half-life	~4 hours (subcutaneous)	~2 hours (short systemic), with sustained tissue effects	~6 days (supports once-weekly dosing)
PK notes	BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~4 hours (subcutaneous). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.	TB-500 is administered subcutaneous or intramuscular injection with an approximate systemic half-life of ~2 hours (short systemic), with sustained tissue effects. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2× per week loading (4 weeks), then 2–5 mg weekly maintenance) is designed to match receptor kinetics rather than plasma exposure. Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.	Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Administration
Typical dose	250–500 mcg	2–5 mg	Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency	1–2× daily	2× per week loading (4 weeks), then 2–5 mg weekly maintenance	Once weekly
Cycle length	4–6 weeks on, 4 weeks off	6–8 week loading phase, then maintenance	Ongoing; weight regain occurs on cessation
Timing	Near site of injury or AM/PM fasted	Any time of day; rotate injection sites	Same day each week; any time of day
Protocol steps	Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily. Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible. Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous or intramuscular injection. Typical starting dose 2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance. Timing: Any time of day; rotate injection sites — keep it the same each dosing day to make effects legible. Cycle length: 6–8 week loading phase, then maintenance. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly. Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible. Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.
Benefits
Reported benefits	Accelerated soft-tissue recovery in preclinical models Gut barrier integrity and ulcer protection Potential nervous system neuroprotection	Accelerated soft-tissue and tendon recovery in preclinical models Improved range of motion after acute injury (case reports) Wound healing and reduced fibrosis Cardiac repair signal in animal MI models	~24% mean weight loss at 48 weeks (Phase II) Marked improvements in HbA1c, blood pressure, ApoB and liver fat Convenient once-weekly dosing Likely best-in-class cardiometabolic profile
Common stacks	TB-500, Collagen peptides, Vitamin C	BPC-157, Collagen peptides, Vitamin C	Creatine monohydrate, Whey protein, Vitamin D3 + K2
Risks
Side effects	Generally well tolerated in animal studies Injection site irritation Long-term human safety unknown	Injection site reactions Temporary lethargy or head rush after dosing Long-term human safety not characterized	Nausea, vomiting, diarrhea (especially during titration) Injection site reactions Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting Theoretical pancreatitis and gallbladder risk (class effect)
Contraindications	Active malignancy (theoretical angiogenic concern) Pregnancy and lactation	Active malignancy (theoretical angiogenic concern) Pregnancy and lactation	Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia type 2 Pregnancy and lactation Prior severe reaction to GLP-1 agonists
Interactions	Anticoagulants — Theoretical synergy via NO modulation — monitor. VEGF inhibitors — Mechanistic opposition; avoid combination.	Anticoagulants — Theoretical effect on tissue remodeling — caution. BPC-157 — Frequently co-stacked; no formal interaction studies.	Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required. Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Legal status	Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.	WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.	Investigational; not yet FDA-approved. Currently available only via clinical trials.

← Back to all peptides